TI
CDAK

Trexquant Investment’s Codiak BioSciences, Inc. Common Stock CDAK Stock Holding History

Trexquant Investment’s Portfolio CDAK Stock Details CDAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-30,068
Closed -$189K – 1976
2022
Q1 		$189K Buy
+30,068
New +$189K 0.01% 1213

Other funds holding CDAK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Trexquant Investment's CDAK Position: Q2 2022 in Review

Trexquant Investment sold out of Codiak BioSciences, Inc. Common Stock (CDAK) in Q2 2022, closing a stake of 30,068 shares — an estimated $189K sold.

Trexquant Investment first reported a position in CDAK in Q1 2022 and held it in 1 quarter. The position peaked at $189K in Q1 2022. 49 funds tracked by Wall St. Rank hold CDAK as of Q2 2022.

  • Trexquant Investment reported no remaining Codiak BioSciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Trexquant Investment sold 30,068 Codiak BioSciences, Inc. Common Stock shares in Q2 2022, an estimated $189K.
  • Trexquant Investment first reported a position in Codiak BioSciences, Inc. Common Stock in Q1 2022 and held it in 1 quarter.
  • Trexquant Investment's Codiak BioSciences, Inc. Common Stock position peaked at $189K in Q1 2022.
  • 49 funds tracked by Wall St. Rank held Codiak BioSciences, Inc. Common Stock as of Q2 2022.

Based on Trexquant Investment's 13F filing for Q2 2022, filed 11 Aug 2022.